<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mem Inst Oswaldo Cruz</journal-id><journal-id journal-id-type="iso-abbrev">Mem. Inst. Oswaldo Cruz</journal-id><journal-title-group><journal-title>Mem&#x000f3;rias do Instituto Oswaldo Cruz</journal-title></journal-title-group><issn pub-type="ppub">0074-0276</issn><issn pub-type="epub">1678-8060</issn><publisher><publisher-name>Instituto Oswaldo Cruz, Minist&#x000e9;rio da Sa&#x000fa;de</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25742269</article-id><article-id pub-id-type="pmc">4371223</article-id><article-id pub-id-type="doi">10.1590/0074-02760140330</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Oseltamivir-resistant influenza A(H1N1)pdm2009 strains found in Brazil
are endowed with permissive mutations, which compensate the loss of fitness imposed
by antiviral resistance</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Souza</surname><given-names>Thiago Moreno Lopes e</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><xref ref-type="corresp" rid="c01">+</xref></contrib><contrib contrib-type="author"><name><surname>Fintelman-Rodrigues</surname><given-names>Natalia</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Resende</surname><given-names>Paola Cristina</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mesquita</surname><given-names>Milene</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gregianini</surname><given-names>Tatiana Schaffer</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bozza</surname><given-names>Fernando A</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pecego</surname><given-names>Ana Carla</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Fernandes</surname><given-names>Sandra Bianchini</given-names></name><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cury</surname><given-names>Ana Luisa Furtado</given-names></name><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Riediger</surname><given-names>Irina Nastassja</given-names></name><xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Siqueira</surname><given-names>Marilda M</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Laborat&#x000f3;rio de V&#x000ed;rus Respirat&#x000f3;rios e do Sarampo</aff><aff id="aff2"><label>2</label>Laborat&#x000f3;rio de Imunofarmacologia, Instituto Oswaldo Cruz</aff><aff id="aff3"><label>3</label>Centro de Desenvolvimento Tecnol&#x000f3;gico em Sa&#x000fa;de, Funda&#x000e7;&#x000e3;o Oswaldo Cruz,
Rio de Janeiro, RJ, Brasil</aff><aff id="aff4"><label>4</label>Laborat&#x000f3;rio Central de Sa&#x000fa;de P&#x000fa;blica do Estado do Rio de Grande do Sul,
Se&#x000e7;&#x000e3;o de Virologia, Funda&#x000e7;&#x000e3;o Estadual de Produ&#x000e7;&#x000e3;o e Pesquisa em Sa&#x000fa;de, Porto Alegre, RS,
Brasil</aff><aff id="aff5"><label>5</label>Laborat&#x000f3;rio de Medicina Intensiva, Instituto de Pesquisas Cl&#x000ed;nicas
Evandro Chagas</aff><aff id="aff6"><label>6</label>Laborat&#x000f3;rio Central de Sa&#x000fa;de P&#x000fa;blica do Estado de Santa Catarina,
Florian&#x000f3;polis, SC, Brasil</aff><aff id="aff7"><label>7</label>Laborat&#x000f3;rio Central de Sa&#x000fa;de P&#x000fa;blica do Estado de Minas Gerais,
Instituto Oct&#x000e1;vio Magalh&#x000e3;es, Funda&#x000e7;&#x000e3;o Ezequiel Dias, Belo Horizonte, MG, Brasil</aff><aff id="aff8"><label>8</label>Laborat&#x000f3;rio Central de Sa&#x000fa;de P&#x000fa;blica do Estado do Paran&#x000e1;, Curitiba, PR,
Brasil</aff><author-notes><corresp id="c01">+ Corresponding author: <email>tmoreno@ioc.fiocruz.br</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>2</month><year>2015</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>2</month><year>2015</year></pub-date><volume>110</volume><issue>1</issue><fpage>101</fpage><lpage>105</lpage><history><date date-type="received"><day>08</day><month>9</month><year>2014</year></date><date date-type="accepted"><day>12</day><month>1</month><year>2015</year></date></history><permissions><license license-type="open-access" xlink:href="0074-0276-mioc-0140330-ghttp://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p></license></permissions><abstract><p>The 2009 pandemic influenza A virus outbreak led to the systematic use of the
neuraminidase (NA) inhibitor oseltamivir (OST). Consequently, OST-resistant strains,
carrying the mutation H275Y, emerged in the years after the pandemics, with a
prevalence of 1-2%. Currently, OST-resistant strains have been found in community
settings, in untreated individuals. To spread in community settings, H275Y mutants
must contain additional mutations, collectively called permissive mutations. We
display the permissive mutations in NA of OST-resistant A(H1N1)pdm09 virus found in
Brazilian community settings. The NAs from 2013 are phylogenetically distinct from
those of 2012, indicating a tendency of positive selection of NAs with better
fitness. Some previously predicted permissive mutations, such as V241I and N369K,
found in different countries, were also detected in Brazil. Importantly, the change
D344N, also predicted to compensate loss of fitness imposed by H275Y mutation, was
found in Brazil, but not in other countries in 2013. Our results reinforce the notion
that OST-resistant A(H1N1)pdm09 strains with compensatory mutations may arise in an
independent fashion, with samples being identified in different states of Brazil and
in different countries. Systematic circulation of these viral strains may jeopardise
the use of the first line of anti-influenza drugs in the future.</p></abstract><kwd-group><kwd>influenza A(H1N1)pdm09</kwd><kwd>oseltamivir</kwd><kwd>antiviral</kwd><kwd>resistance</kwd><kwd>H275Y</kwd><kwd>permissive mutation</kwd></kwd-group><counts><fig-count count="2"/><table-count count="1"/><ref-count count="23"/><page-count count="1"/></counts></article-meta></front><body><p>Anti-influenza drugs are essential for prophylactic and therapeutic interventions. Since
antiviral resistance to adamantanes is very common (<xref rid="B16" ref-type="bibr">Santesso et al. 2013</xref>), neuraminidase inhibitors (NAI) have become the main class
of anti-influenza drugs in clinical use. Among NAIs, oseltamivir (OST) use has grown since
the emergence of 2009 pandemic influenza A [A(H1N1)pdm09]. Consequently, the pressure
imposed by OST on A(H1N1)pdm09 has led to the selection of OST-resistant mutants, with a
prevalence of 1-2% in different countries (<xref rid="B07" ref-type="bibr">Dixit et al.
2013</xref>). Remarkably, community transmission of OST-resistant influenza A(H1N1)pdm09
has drawn special attention because mutation H275Y in the neuraminidase (NA) may decrease
viral fitness (<xref rid="B12" ref-type="bibr">Kelso &#x00026; Hurt 2012</xref> ).
Nevertheless, the H275Y change may emerge in a NA endowed with permissive mutations (<xref rid="B12" ref-type="bibr">Kelso &#x00026; Hurt 2012</xref>), which compensates for the
decrease in viral fitness imposed by OST resistance. Viral strains carrying predicted
permissive mutations have been circulating (<xref rid="B08" ref-type="bibr">Hurt et al.
2011, 2012</xref>, <xref rid="B12" ref-type="bibr">Kelso &#x00026; Hurt 2012</xref>, <xref rid="B04" ref-type="bibr">CDC 2013</xref>, <xref rid="B20" ref-type="bibr">Takashita et
al. 2014</xref>, <xref rid="B23" ref-type="bibr">Zaraket et al. 2014</xref>, <xref rid="B05" ref-type="bibr">Correia et al. 2015</xref>) and may have been responsible for
A(H1N1)pdm09 OST-resistant outbreaks in community settings (Hurt et al. 2011, 2012, <xref rid="B13" ref-type="bibr">Lackenby et al. 2011</xref>, <xref rid="B12" ref-type="bibr">Kelso &#x00026; Hurt 2012</xref>, <xref rid="B18" ref-type="bibr">Storms et al.
2012</xref>, <xref rid="B04" ref-type="bibr">CDC 2013</xref>, <xref rid="B17" ref-type="bibr">Souza et al. 2013</xref>, <xref rid="B20" ref-type="bibr">Takashita et al.
2014</xref>, <xref rid="B23" ref-type="bibr">Zaraket et al. 2014</xref>, <xref rid="B05" ref-type="bibr">Correia et al. 2015</xref>). The largest cluster of community
spread of OST-resistant A(H1N1)pdm09 occurred in Australia, with cases detected in cities
4,000 km apart (Hurt et al. 2011, 2012). In Brazil during 2012, we found an overall
incidence of 1.19% of OST-resistant strains of influenza A(H1N1)pdm09 (<xref rid="B17" ref-type="bibr">Souza et al. 2013</xref>), with community spread in cities 535
km apart. In the current study, 2013 influenza A(H1N1)pdm09 surveillance data reveals the
circulation of OST-resistant strains with predicted permissive mutations, detected by
Sanger sequencing, in community settings in Brazil.</p><sec><title>SUBJECTS, MATERIALS AND METHODS</title><p>
<italic>Ethics </italic>- Since influenza surveillance is covered by Brazilian public
health policies and all data were analysed in an anonymous fashion, ethical committee
approval and need for informed consent have been waived, as previously described (<xref rid="B17" ref-type="bibr">Souza et al. 2013</xref>).</p><p>
<italic>Patients and data collection</italic> - A sub-set of samples from patients
displaying acute symptoms of respiratory infection (fever, &#x0003e; 37.8&#x000ba;C and respiratory
influenza-like illness) (<xref rid="B22" ref-type="bibr">WHO 2011</xref> ) were
collected and sent to the National Influenza Centre (NIC) in Brazil. Patients were
treated according to Brazilian guidelines for influenza management (<xref rid="B15" ref-type="bibr">MS 2009</xref>). Patients' information, such as name
initials, gender, age, city/state of onset of illness and the dates of the beginning of
the symptoms and sample collection, were registered.</p><p>
<italic>Sample collection and diagnosis</italic> - Nasopharyngeal aspirates or Dacron
swabs were collected and RNA was extracted using a viral RNA mini kit (QIAGEN, USA),
according to the manufacturer's instructions. One-step real-time reverse
transcription-polymerase chain reaction (RT-PCR) assays for influenza subtyping were
performed according to the World Health Organization (WHO) recommendations (<xref rid="B22" ref-type="bibr">WHO 2011</xref>).</p><p>
<italic>Cells and virus isolation</italic> - Madin-Darby canine kidney cells (London
line) were kindly donated by the Centers of Disease Control and Prevention (CDC),
Influenza Reagent Resources (FR-58). These cells were cultured in Dulbecco's modified
Eagle's medium (GIBCO, USA) supplemented with 10% foetal bovine serum (Hyclone, USA),
100 U/mL penicillin and 100 &#x000b5;g/mL streptomycin and were incubated at 37&#x000ba;C in 5%
CO<sub>2</sub> (<xref rid="B22" ref-type="bibr">WHO 2011</xref>). The virus isolation
was done according to WHO international protocol (<xref rid="B22" ref-type="bibr">WHO
2011</xref>). We confirmed viral isolation by NA activity (<xref rid="B19" ref-type="bibr">Szretter et al. 2006</xref>, <xref rid="B21" ref-type="bibr">WHO
2009</xref>, <xref rid="B22" ref-type="bibr">2011</xref>). Viruses were passaged no
more than two times.</p><p>
<italic>Functional antiviral assay</italic> - To determine the half maximum inhibitory
concentration (IC<sub>50</sub>) values of our samples to OST carboxylate, we performed
functional antiviral assays using the NA-Star<sup>TM</sup> assay kit (Life Technologies,
USA), according to the manufacturer's instructions (<xref rid="B17" ref-type="bibr">Souza et al. 2013</xref>). Assays with wild-type and resistant strains of influenza
A(H1N1)pdm09, A/Perth/265/2009 and A/Perth/261/2009, respectively, were performed as a
control. These control strains were kindly donated by International Society for
Influenza and other Respiratory Viruses Diseases-Antiviral Group, Neuraminidase
Inhibitor Susceptibility Network.</p><p>
<italic>Molecular antiviral assays</italic> - Single nucleotide polymorphisms in the NA
gene were analysed by pyrosequencing, as described previously (<xref rid="B06" ref-type="bibr">Deyde et al. 2010</xref>).</p><p>The NA gene was sequenced by Sanger sequencing according to a protocol described
elsewhere (<xref rid="B01" ref-type="bibr">Baillie et al. 2012</xref>). The amplified
RT-PCR products were purified using the QIAquick PCR Purification kit (QIAGEN) and
sequenced using a BigDye Terminator v.3.1 Cycle Sequencing kit (Life Technologies). The
products were analysed in an ABI Prism 3130XL genetic analyser (Life Technologies).
Sequences with the mutation H275Y found in our analysis were deposited in GenBank
(accessions KC984901, KC984933, KJ493404 and KJ493405). The data generated were
assembled in Sequencher 5.0 software (GeneCodes Corporation, USA) with an NA reference
sequence, A/California/4/2009 (GenBank accession FJ966084). N1 numbering was used for NA
throughout this study.</p></sec><sec><title>RESULTS AND DISCUSSION</title><p>In 2013, the Brazilian NIC received 1,498 specimens from individuals with acute
respiratory infection, encompassing samples from three out of five Brazilian Regions.
Among these, 310 were positive for influenza virus A(H1N1)pdm09. Most of the cases were
concentrated in the southern (52.9%) and southeastern (31.3%) regions of Brazil. The
analysed samples were collected mainly during autumn (28.4%) and winter (36.1%). Based
on clinical-epidemiological forms completed, symptoms of severe acute respiratory
infection were found in 2% of the patients, vaccines accounted for 13.5% of the
individuals, comorbidities were registered in 13.9% of the patients and 7.7% deceased.
OST-treated patients accounted for 15.9% of the individuals analysed. Among all
confirmed cases of A(H1N1)pdm09, 208 samples presented reliable pyrograms, with respect
to screening for the H275Y mutation (<xref rid="B06" ref-type="bibr">Deyde et al.
2010</xref>). Two specimens contained A(H1N1)pdm09 virus with the H275Y amino acid
substitution indicative for OST resistance were found (<xref ref-type="table" rid="t01">Table</xref>). These were from individuals with no registered use of OST (<xref ref-type="table" rid="t01">Table</xref>), as occurred in 2012 (<xref rid="B17" ref-type="bibr">Souza et al. 2013</xref>). The IC<sub>50</sub> values for sensitive strains
(n = 206) isolated in 2013 were 0.5 &#x000b1; 0.4 nM (mean &#x000b1; standard deviation) and the
IC<sub>50</sub> values for resistant strains were 102 and 116 nM (<xref ref-type="table" rid="t01">Table</xref>).</p><p>
<table-wrap id="t01" orientation="portrait" position="float"><label>TABLE</label><caption><title>Viral characteristics and clinical aspects of patients in which oseltamivir
(OST)-resistant samples were detected</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Patients</th><th rowspan="1" colspan="1">Mutations</th><th rowspan="1" colspan="1">IC<sub>50</sub>(nM)</th><th rowspan="1" colspan="1">Region</th><th rowspan="1" colspan="1">State</th><th rowspan="1" colspan="1">Age</th><th rowspan="1" colspan="1">Gender</th><th rowspan="1" colspan="1">Symptoms onset(date)</th><th rowspan="1" colspan="1">Sample collection(date)</th><th rowspan="1" colspan="1">OST use</th><th rowspan="1" colspan="1">Deceased</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">H275Y</td><td align="center" rowspan="1" colspan="1">102</td><td align="center" rowspan="1" colspan="1">Southeast</td><td align="center" rowspan="1" colspan="1">RJ</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">2 April 2013</td><td align="center" rowspan="1" colspan="1">5 April 2013</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">H275Y</td><td align="center" rowspan="1" colspan="1">116</td><td align="center" rowspan="1" colspan="1">South</td><td align="center" rowspan="1" colspan="1">RS</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">26 March 2013</td><td align="center" rowspan="1" colspan="1">5 April 2013</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr></tbody></table><table-wrap-foot><fn id="t01TFN01"><p>IC50: the half maximum inhibitory concentration; OST: oseltamivir; RJ: Rio
de Janeiro; RS: Rio Grande do Sul.</p></fn></table-wrap-foot></table-wrap>
</p><p>In general, viral strains found in Brazilian community settings from 2013 clustered in a
different branch than those from 2012 (<xref ref-type="fig" rid="f01">Fig. 1</xref>)
(H275Y viruses in red). This temporal segregation of NA sequences may suggest a tendency
of positive selection of A(H1N1)pdm09 NAs. It is therefore likely that viruses with
these NAs are better adapted to propagate in their hosts than the predecessor strains.
The NA from Brazilian strains from 2012 and 2013 had the changes V241I and N369K in
common. These mutations have been found in Brazil since 2011 (<xref ref-type="fig" rid="f01">Fig. 1</xref>) and are predicted to compensate for the negative effects of
H275Y change (Hurt et al. 2012, <xref rid="B03" ref-type="bibr">Butler et al.
2014</xref>). The V241I and N369K enhance NA expression and activity in in vitro
studies and this effect improve A(H1N1)pdm09 fitness (<xref rid="B03" ref-type="bibr">Butler et al. 2014</xref>). These two changes have also been found in the community
cluster of OST-resistant A(H1N1)pdm09 in the United States of America (USA), Australia
and Japan (Hurt et al. 2012, <xref rid="B04" ref-type="bibr">CDC 2013</xref>, <xref rid="B20" ref-type="bibr">Takashita et al. 2014</xref>). The permissive mutation
N386K, on the other hand, was found in Australia and Japan (Hurt et al. 2012, <xref rid="B20" ref-type="bibr">Takashita et al. 2014</xref>), but not in the Americas
(neither in USA or Brazil). Differently than Australian samples, Japanese, North
American and Brazilian samples from 2013 had the change N200S (Storms et al. 2012, <xref rid="B20" ref-type="bibr">Takashita et al. 2014</xref>). Remarkably, one Brazilian
sample from 2013 had the change D344N, which is predicted to occur in A(H1N1)pdm09 NA by
<italic>in silico</italic> data and capable of compensating for the reduction in NA
activity by H275Y (<xref rid="B02" ref-type="bibr">Bloom et al. 2011</xref>). In
addition, other changes of apparently minor importance occurred in the NA sequences
shown in red in the phylogenetic tree (<xref ref-type="fig" rid="f01">Fig. 1</xref>)
(GenBank accessions KC984901, KC984933, KJ493404 and KJ493405). For example, the
mutations N42S (2012) and N44S (2013) may create new glycosylation sites (Hurt et al.
2012). Moreover, we also found mutations in the A(H1N1)pdm09 NA close to their
equivalent amino acid residues in the widely disseminated OST-resistant seasonal H1N1
(<xref rid="B14" ref-type="bibr">Meijer et al. 2007</xref>, Hurt et al. 2009, 2012);
such as S79P, I188T and N225D.</p><p>
<fig id="f01" orientation="portrait" position="float"><label>Fig. 1:</label><caption><title>phylogenetic tree neuraminidase (NA) sequences from Brazil.
Maximum-likelihood (ML) phylogenetic tree with NA from influenza A(H1N1)pdm09
viruses circulating in Brazil from 2009-2013, rooted by NA sequences from
A/California/4/2009 and A/California/7/2009. Sequences with the mutation H275Y
are shown in red. Amino acid changes associated with these specific clusters
are indicated in the nodes using N1 numbering. ML reliability of branches was
evaluated using approximate likelihood-ratio test and the interior branch
cut-off values &#x02265; 0.9 are represented by asterisks.</title></caption><graphic xlink:href="0074-0276-mioc-110-01-00101-gf01"/></fig>
</p><p>For public health concerns, H275Y viruses from 2012 were found in the cities of Foz do
Igua&#x000e7;u (state of Paran&#x000e1;) and Florian&#x000f3;polis (state of Santa Catarina) (<xref rid="B17" ref-type="bibr">Souza et al. 2013</xref>), whereas the two samples from
2013 were collected in Nova Igua&#x000e7;u (NIG) (state of Rio de Janeiro) and Porto Alegre
(POA) (state of Rio Grande do Sul) (<xref ref-type="fig" rid="f02">Fig. 2</xref>). NIG
and POA are cities around 1,490 km apart and have population densities of 1,527.60 and
2,837.52 inhabitant/km<sup>2 </sup>(<xref rid="B11" ref-type="bibr">IBGE 2010</xref>),
respectively. High population densities, such as these, increase the risk of respiratory
virus infection and highlight the potential to spread OST-resistant variants.
Considering the data from 2012 and 2013, an area of over 271,817 km<sup>2 </sup>could be
exposed to OST-resistant A(H1N1)pdm09 found in community settings. Remarkably, this area
is within the southern and southeastern Brazilian regions, in which influenza activities
are higher due to transition from a temperate to tropical climate.</p><p>
<fig id="f02" orientation="portrait" position="float"><label>Fig. 2:</label><caption><title>geographic detection of oseltamivir (OST)-resistant influenza A(H1N1)pdm09
strains in community settings. This map shows the Southern Cone of Brazil and
neighbour Latin American countries. OST-resistant influenza A(H1N1)pdm09
detected in community settings in 2012 and 2013 are highlighted in red and
yellow, respectively. This map has been generated with the R-program.</title></caption><graphic xlink:href="0074-0276-mioc-110-01-00101-gf02"/></fig>
</p><p>Our data not only suggests that OST-resistant strains may be present in an even broader
area of Brazil or South America, than previously thought (<xref rid="B17" ref-type="bibr">Souza et al. 2013</xref>), but also draws special attention to the
community detection of influenza A(H1N1)pdm09 H275Y in highly populous developing
countries in which antiviral resistance surveillance may be neglected. Although low
prevalence of H275Y viruses with permissive mutations in the NA is comparable to what is
found in other countries, this information is critical for further drug stockpiling and
pandemic preparedness.</p></sec></body><back><ack><title>ACKNOWLEDGEMENTS</title><p>To IOC/Fiocruz, for providing PCR and NFR fellowships, and to Ms Sharon Carney, for
reviewing the paper.</p></ack><fn-group><fn fn-type="supported-by"><p>Financial support: FIOCRUZ, MS/DECIT-SVS MMS was supported in part by individual
research from CNPq, MMS and TMLS used in part individual research from FAPERJ and
CNPq.</p></fn></fn-group><ref-list><ref id="B01"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baillie</surname><given-names>GJ</given-names></name><name><surname>Galiano</surname><given-names>M</given-names></name><name><surname>Agapow</surname><given-names>PM</given-names></name><name><surname>Myers</surname><given-names>R</given-names></name><name><surname>Chiam</surname><given-names>R</given-names></name><name><surname>Gall</surname><given-names>A</given-names></name><name><surname>Palser</surname><given-names>AL</given-names></name><name><surname>Watson</surname><given-names>SJ</given-names></name><name><surname>Hedge</surname><given-names>J</given-names></name><name><surname>Underwood</surname><given-names>A</given-names></name><name><surname>Platt</surname><given-names>S</given-names></name><name><surname>McLean</surname><given-names>E</given-names></name><name><surname>Pebody</surname><given-names>RG</given-names></name><name><surname>Rambaut</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>J</given-names></name><name><surname>Daniels</surname><given-names>R</given-names></name><name><surname>Pybus</surname><given-names>OG</given-names></name><name><surname>Kellam</surname><given-names>P</given-names></name><name><surname>Zambon</surname><given-names>M</given-names></name></person-group><year>2012</year><article-title>Evolutionary dynamics of local pandemic H1N1/2009 influenza virus
lineages revealed by whole-genome analysis</article-title><source>J Virol</source><volume>86</volume><fpage>11</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">22013031</pub-id></element-citation></ref><ref id="B02"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloom</surname><given-names>JD</given-names></name><name><surname>Nayak</surname><given-names>JS</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group><year>2011</year><article-title>A computational-experimental approach identifies mutations that
enhance surface expression of an oseltamivir-resistant influenza
neuraminidase</article-title><source>PLoS ONE</source><volume>6</volume><fpage>e22201</fpage><lpage>e22201</lpage><pub-id pub-id-type="pmid">21799795</pub-id></element-citation></ref><ref id="B03"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>J</given-names></name><name><surname>Hooper</surname><given-names>KA</given-names></name><name><surname>Petrie</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>R</given-names></name><name><surname>Maurer-Stroh</surname><given-names>S</given-names></name><name><surname>Reh</surname><given-names>L</given-names></name><name><surname>Guarnaccia</surname><given-names>T</given-names></name><name><surname>Baas</surname><given-names>C</given-names></name><name><surname>Xue</surname><given-names>L</given-names></name><name><surname>Vitesnik</surname><given-names>S</given-names></name><name><surname>Leang</surname><given-names>SK</given-names></name><name><surname>McVernon</surname><given-names>J</given-names></name><name><surname>Kelso</surname><given-names>A</given-names></name><name><surname>Barr</surname><given-names>IG</given-names></name><name><surname>McCaw</surname><given-names>JM</given-names></name><name><surname>Bloom</surname><given-names>JD</given-names></name><name><surname>Hurt</surname><given-names>AC</given-names></name></person-group><year>2014</year><article-title>Estimating the fitness advantage conferred by permissive neuraminidase
mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza
viruses</article-title><source>PLoS Pathog</source><volume>10</volume><fpage>e1004065</fpage><lpage>e1004065</lpage><pub-id pub-id-type="pmid">24699865</pub-id></element-citation></ref><ref id="B04"><element-citation publication-type="book"><person-group person-group-type="author"><collab>CDC - Centers for Disease Control and Prevention</collab></person-group><year>2013</year><source>Weekly U.S. Influenza Surveillance Report. FluView. A weekly influenza
surveillance report prepared by the Influenza Division. 2013-2014 influenza season
week 51 ending December 21, 2013</source><ext-link ext-link-type="uri" xlink:href="cdc.gov/flu/weekly/">cdc.gov/flu/weekly/</ext-link></element-citation></ref><ref id="B05"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correia</surname><given-names>V</given-names></name><name><surname>Santos</surname><given-names>LA</given-names></name><name><surname>Giria</surname><given-names>M</given-names></name><name><surname>Almeida-Santos</surname><given-names>MM</given-names></name><name><surname>Rebelo-de-Andrade</surname><given-names>H</given-names></name></person-group><year>2015</year><article-title>Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility
to oseltamivir and zanamivir antiviral drugs</article-title><source>J Med Virol</source><volume>87</volume><fpage>45</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">25042157</pub-id></element-citation></ref><ref id="B06"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deyde</surname><given-names>VM</given-names></name><name><surname>Sheu</surname><given-names>TG</given-names></name><name><surname>Trujillo</surname><given-names>AA</given-names></name><name><surname>Okomo-Adhiambo</surname><given-names>M</given-names></name><name><surname>Garten</surname><given-names>R</given-names></name><name><surname>Klimov</surname><given-names>AI</given-names></name><name><surname>Gubareva</surname><given-names>LV</given-names></name></person-group><year>2010</year><article-title>Detection of molecular markers of drug resistance in 2009 pandemic
influenza A (H1N1) viruses by pyrosequencing</article-title><source>Antimicrob Agents Chemother</source><volume>54</volume><fpage>1102</fpage><lpage>1110</lpage><pub-id pub-id-type="pmid">20028826</pub-id></element-citation></ref><ref id="B07"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixit</surname><given-names>R</given-names></name><name><surname>Khandaker</surname><given-names>G</given-names></name><name><surname>Ilgoutz</surname><given-names>S</given-names></name><name><surname>Rashid</surname><given-names>H</given-names></name><name><surname>Booy</surname><given-names>R</given-names></name></person-group><year>2013</year><article-title>Emergence of oseltamivir resistance: control and management of
influenza before, during and after the pandemic</article-title><source>Infect Disord Drug Targets</source><volume>13</volume><fpage>34</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">23675925</pub-id></element-citation></ref><ref id="B08"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurt</surname><given-names>AC</given-names></name><name><surname>Ernest</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>YM</given-names></name><name><surname>Iannello</surname><given-names>P</given-names></name><name><surname>Besselaar</surname><given-names>TG</given-names></name><name><surname>Birch</surname><given-names>C</given-names></name><name><surname>Buchy</surname><given-names>P</given-names></name><name><surname>Chittaganpitch</surname><given-names>M</given-names></name><name><surname>Chiu</surname><given-names>SC</given-names></name><name><surname>Dwyer</surname><given-names>D</given-names></name><name><surname>Guigon</surname><given-names>A</given-names></name><name><surname>Harrower</surname><given-names>B</given-names></name><name><surname>Kei</surname><given-names>IP</given-names></name><name><surname>Kok</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>McPhie</surname><given-names>K</given-names></name><name><surname>Mohd</surname><given-names>A</given-names></name><name><surname>Olveda</surname><given-names>R</given-names></name><name><surname>Panayotou</surname><given-names>T</given-names></name><name><surname>Rawlinson</surname><given-names>W</given-names></name><name><surname>Scott</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>D'Souza</surname><given-names>H</given-names></name><name><surname>Komadina</surname><given-names>N</given-names></name><name><surname>Shaw</surname><given-names>R</given-names></name><name><surname>Kelso</surname><given-names>A</given-names></name><name><surname>Barr</surname><given-names>IG</given-names></name></person-group><year>2009</year><article-title>Emergence and spread of oseltamivir-resistant A(H1N1) influenza
viruses in Oceania, South East Asia and South Africa</article-title><source>Antiviral Res</source><volume>83</volume><fpage>90</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">19501261</pub-id></element-citation></ref><ref id="B09"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurt</surname><given-names>AC</given-names></name><name><surname>Hardie</surname><given-names>K</given-names></name><name><surname>Wilson</surname><given-names>NJ</given-names></name><name><surname>Deng</surname><given-names>YM</given-names></name><name><surname>Osbourn</surname><given-names>M</given-names></name><name><surname>Gehrig</surname><given-names>N</given-names></name><name><surname>Kelso</surname><given-names>A</given-names></name></person-group><year>2011</year><article-title>Community transmission of oseltamivir-resistant A(H1N1)pdm09
influenza</article-title><source>N Engl J Med</source><volume>365</volume><fpage>2541</fpage><lpage>2542</lpage><pub-id pub-id-type="pmid">22204735</pub-id></element-citation></ref><ref id="B10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurt</surname><given-names>AC</given-names></name><name><surname>Hardie</surname><given-names>K</given-names></name><name><surname>Wilson</surname><given-names>NJ</given-names></name><name><surname>Deng</surname><given-names>YM</given-names></name><name><surname>Osbourn</surname><given-names>M</given-names></name><name><surname>Leang</surname><given-names>SK</given-names></name><name><surname>Lee</surname><given-names>RT</given-names></name><name><surname>Iannello</surname><given-names>P</given-names></name><name><surname>Gehrig</surname><given-names>N</given-names></name><name><surname>Shaw</surname><given-names>R</given-names></name><name><surname>Wark</surname><given-names>P</given-names></name><name><surname>Caldwell</surname><given-names>N</given-names></name><name><surname>Givney</surname><given-names>RC</given-names></name><name><surname>Xue</surname><given-names>L</given-names></name><name><surname>Maurer-Stroh</surname><given-names>S</given-names></name><name><surname>Dwyer</surname><given-names>DE</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Smith</surname><given-names>DW</given-names></name><name><surname>Levy</surname><given-names>A</given-names></name><name><surname>Booy</surname><given-names>R</given-names></name><name><surname>Dixit</surname><given-names>R</given-names></name><name><surname>Merritt</surname><given-names>T</given-names></name><name><surname>Kelso</surname><given-names>A</given-names></name><name><surname>Dalton</surname><given-names>C</given-names></name><name><surname>Durrheim</surname><given-names>D</given-names></name><name><surname>Barr</surname><given-names>IG</given-names></name></person-group><year>2012</year><article-title>Characteristics of a widespread community cluster of H275Y
oseltamivir-resistant A(H1N1)pdm09 influenza in Australia</article-title><source>J Infect Dis</source><volume>206</volume><fpage>148</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">22561367</pub-id></element-citation></ref><ref id="B11"><element-citation publication-type="book"><person-group person-group-type="author"><collab>IBGE - Instituto Brasileiro de Geografia e Estat&#x000ed;stica</collab></person-group><year>2010</year><source>Censo 2010</source><ext-link ext-link-type="uri" xlink:href="censo2010.ibge.gov.br">censo2010.ibge.gov.br</ext-link></element-citation></ref><ref id="B12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelso</surname><given-names>A</given-names></name><name><surname>Hurt</surname><given-names>AC</given-names></name></person-group><year>2012</year><article-title>The ongoing battle against influenza: drug-resistant influenza
viruses: why fitness matters</article-title><source>Nat Med</source><volume>18</volume><fpage>1470</fpage><lpage>1471</lpage><pub-id pub-id-type="pmid">23042350</pub-id></element-citation></ref><ref id="B13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lackenby</surname><given-names>A</given-names></name><name><surname>Gilad</surname><given-names>JM</given-names></name><name><surname>Pebody</surname><given-names>R</given-names></name><name><surname>Miah</surname><given-names>S</given-names></name><name><surname>Calatayud</surname><given-names>L</given-names></name><name><surname>Bolotin</surname><given-names>S</given-names></name><name><surname>Vipond</surname><given-names>I</given-names></name><name><surname>Muir</surname><given-names>P</given-names></name><name><surname>Guiver</surname><given-names>M</given-names></name><name><surname>McMenamin</surname><given-names>J</given-names></name><name><surname>Reynolds</surname><given-names>A</given-names></name><name><surname>Moore</surname><given-names>C</given-names></name><name><surname>Gunson</surname><given-names>R</given-names></name><name><surname>Thompson</surname><given-names>C</given-names></name><name><surname>Galiano</surname><given-names>M</given-names></name><name><surname>Bermingham</surname><given-names>A</given-names></name><name><surname>Ellis</surname><given-names>J</given-names></name><name><surname>Zambon</surname><given-names>M</given-names></name></person-group><year>2011</year><article-title>Continued emergence and changing epidemiology of oseltamivir-resistant
influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11</article-title><source>Euro Surveill</source><volume>16</volume><fpage>19784</fpage><lpage>19784</lpage><pub-id pub-id-type="pmid">21315056</pub-id></element-citation></ref><ref id="B14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meijer</surname><given-names>A</given-names></name><name><surname>Lackenby</surname><given-names>A</given-names></name><name><surname>Hay</surname><given-names>A</given-names></name><name><surname>Zambon</surname><given-names>M</given-names></name></person-group><year>2007</year><article-title>Influenza antiviral susceptibility monitoring activities in relation
to national antiviral stockpiles in Europe during the winter 2006/2007
season</article-title><source>Euro Surveill</source><volume>12</volume><fpage>E3</fpage><lpage>E4</lpage><pub-id pub-id-type="pmid">17991386</pub-id></element-citation></ref><ref id="B15"><element-citation publication-type="book"><person-group person-group-type="author"><collab>MS - Minist&#x000e9;rio da Sa&#x000fa;de Brasil</collab></person-group><year>2009</year><source>Protocolo de manejo cl&#x000ed;nico e vigil&#x000e2;ncia epidemiol&#x000f3;gica da influenza, vers&#x000e3;o
III</source><publisher-name>MS</publisher-name><publisher-loc>Bras&#x000ed;lia</publisher-loc><size units="pages">32</size></element-citation></ref><ref id="B16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santesso</surname><given-names>N</given-names></name><name><surname>Hsu</surname><given-names>J</given-names></name><name><surname>Mustafa</surname><given-names>R</given-names></name><name><surname>Brozek</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>YL</given-names></name><name><surname>Hopkins</surname><given-names>JP</given-names></name><name><surname>Cheung</surname><given-names>A</given-names></name><name><surname>Hovhannisyan</surname><given-names>G</given-names></name><name><surname>Ivanova</surname><given-names>L</given-names></name><name><surname>Flottorp</surname><given-names>SA</given-names></name><name><surname>Saeterdal</surname><given-names>I</given-names></name><name><surname>Wong</surname><given-names>AD</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Uyeki</surname><given-names>TM</given-names></name><name><surname>Akl</surname><given-names>EA</given-names></name><name><surname>Alonso-Coello</surname><given-names>P</given-names></name><name><surname>Smaill</surname><given-names>F</given-names></name><name><surname>Sch&#x000fc;nemann</surname><given-names>HJ</given-names></name></person-group><year>2013</year><article-title>Antivirals for influenza: a summary of a systematic review and
meta-analysis of observational studies</article-title><source>Influenza Other Respir Viruses</source><volume>7 (Suppl. 2)</volume><fpage>76</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">24034489</pub-id></element-citation></ref><ref id="B17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souza</surname><given-names>TM</given-names></name><name><surname>Resende</surname><given-names>PC</given-names></name><name><surname>Fintelman-Rodrigues</surname><given-names>N</given-names></name><name><surname>Gregianini</surname><given-names>TS</given-names></name><name><surname>Ikuta</surname><given-names>N</given-names></name><name><surname>Fernandes</surname><given-names>SB</given-names></name><name><surname>Cury</surname><given-names>AL</given-names></name><name><surname>Rosa</surname><given-names>MC</given-names></name><name><surname>Siqueira</surname><given-names>MM</given-names></name></person-group><year>2013</year><article-title>Detection of oseltamivir-resistant pandemic influenza A(H1N1)pdm2009
in Brazil: can community transmission be ruled out?</article-title><source>PLoS ONE</source><volume>8</volume><fpage>e80081</fpage><lpage>e80081</lpage><pub-id pub-id-type="pmid">24244615</pub-id></element-citation></ref><ref id="B18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Storms</surname><given-names>AD</given-names></name><name><surname>Gubareva</surname><given-names>LV</given-names></name><name><surname>Su</surname><given-names>S</given-names></name><name><surname>Wheeling</surname><given-names>JT</given-names></name><name><surname>Okomo-Adhiambo</surname><given-names>M</given-names></name><name><surname>Pan</surname><given-names>CY</given-names></name><name><surname>Reisdorf</surname><given-names>E</given-names></name><name><surname>George</surname><given-names>KS</given-names></name><name><surname>Myers</surname><given-names>R</given-names></name><name><surname>Wotton</surname><given-names>JT</given-names></name><name><surname>Robinson</surname><given-names>S</given-names></name><name><surname>Leader</surname><given-names>B</given-names></name><name><surname>Thompson</surname><given-names>M</given-names></name><name><surname>Shannon</surname><given-names>M</given-names></name><name><surname>Klimov</surname><given-names>A</given-names></name><name><surname>Fry</surname><given-names>AM</given-names></name></person-group><year>2012</year><article-title>Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United
States, 2010-11</article-title><source>Emerg Infect Dis</source><volume>18</volume><fpage>308</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">22305467</pub-id></element-citation></ref><ref id="B19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szretter</surname><given-names>KJ</given-names></name><name><surname>Balish</surname><given-names>AL</given-names></name><name><surname>Katz</surname><given-names>JM</given-names></name></person-group><year>2006</year><article-title>Influenza: propagation, quantification and storage</article-title><source>Curr Protoc Microbiol</source><volume>3</volume><fpage>C15</fpage><lpage>U15G</lpage></element-citation></ref><ref id="B20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takashita</surname><given-names>E</given-names></name><name><surname>Ejima</surname><given-names>M</given-names></name><name><surname>Itoh</surname><given-names>R</given-names></name><name><surname>Miura</surname><given-names>M</given-names></name><name><surname>Ohnishi</surname><given-names>A</given-names></name><name><surname>Nishimura</surname><given-names>H</given-names></name><name><surname>Odagiri</surname><given-names>T</given-names></name><name><surname>Tashiro</surname><given-names>M</given-names></name></person-group><year>2014</year><article-title>A community cluster of influenza A(H1N1)pdm09 virus exhibiting
cross-resistance to oseltamivir and peramivir in Japan, November to December
2013</article-title><source>Euro Surveill</source><volume>19</volume><fpage>20666</fpage><lpage>20666</lpage><pub-id pub-id-type="pmid">24434172</pub-id></element-citation></ref><ref id="B21"><element-citation publication-type="book"><person-group person-group-type="author"><collab>WHO - World Health Organization</collab></person-group><year>2009</year><source>CDC protocol of realtime RTPCR for influenza A(H1N1)</source><ext-link ext-link-type="uri" xlink:href="0074-0276-mioc-0140330-g0074-0276-mioc-0140330-gwho.int/csr/resources/publications/swineflu/realtimeptpcr/en/.">who.int/csr/resources/publications/swineflu/realtimeptpcr/en/.</ext-link></element-citation></ref><ref id="B22"><element-citation publication-type="book"><person-group person-group-type="author"><collab>WHO - World Health Organization</collab></person-group><year>2011</year><source>WHO Global Influenza Network 2011.Manual for the laboratory diagnosis and
virological surveillance of influenza</source><publisher-name>WHO</publisher-name><publisher-loc>Geneva</publisher-loc><size units="pages">139</size></element-citation></ref><ref id="B23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaraket</surname><given-names>H</given-names></name><name><surname>Dapat</surname><given-names>C</given-names></name><name><surname>Ghanem</surname><given-names>S</given-names></name><name><surname>Ali</surname><given-names>Z</given-names></name><name><surname>Lteif</surname><given-names>M</given-names></name><name><surname>Kondo</surname><given-names>H</given-names></name><name><surname>Dapat</surname><given-names>IC</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Kayali</surname><given-names>G</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Dbaibo</surname><given-names>G</given-names></name><name><surname>Saito</surname><given-names>R</given-names></name></person-group><year>2014</year><article-title>Characterization of human influenza viruses in Lebanon during
2010-2011 and 2011-2012 post-pandemic seasons</article-title><source>Intervirology</source><volume>57</volume><fpage>344</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">25301400</pub-id></element-citation></ref></ref-list></back></article>